The estimated Net Worth of Parisa Zamiri is at least $1.45 Million dollars as of 3 March 2023. Dr Zamiri owns over 120,655 units of Graybug Vision stock worth over $980,276 and over the last 4 years he sold GRAY stock worth over $0. In addition, he makes $468,514 as Chief Medical Officer at Graybug Vision.
Dr has made over 5 trades of the Graybug Vision stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 120,655 units of GRAY stock worth $663,603 on 3 March 2023.
The largest trade he's ever made was exercising 120,655 units of Graybug Vision stock on 3 March 2023 worth over $663,603. On average, Dr trades about 20,503 units every 29 days since 2020. As of 3 March 2023 he still owns at least 178,232 units of Graybug Vision stock.
You can see the complete history of Dr Zamiri stock trades at the bottom of the page.
Dr. Parisa Zamiri M.D., Ph.D. is the Chief Medical Officer at Graybug Vision.
As the Chief Medical Officer of Graybug Vision, the total compensation of Dr D at Graybug Vision is $468,514. There are 2 executives at Graybug Vision getting paid more, with Dr. Frederic Guerard Pharm.D. having the highest compensation of $931,025.
Dr D is 56, he's been the Chief Medical Officer of Graybug Vision since . There are 5 older and 2 younger executives at Graybug Vision. The oldest executive at Graybug Vision, Inc. is Dr. Gerald D. Cagle Ph.D., 77, who is the Sr. Advisor, Head of Bus. Devel. & Director.
Parisa's mailing address filed with the SEC is C/O GRAYBUG VISION, INC., 274 REDWOOD SHORES PARKWAY, PO BOX 144, REDWOOD CITY, CA, 94065.
Over the last 4 years, insiders at Graybug Vision have traded over $0 worth of Graybug Vision stock and bought 2,393,750 units worth $38,300,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., James E Deerfield Mgmt Hif,..., and Frederic Guerard. On average, Graybug Vision executives and independent directors trade stock every 35 days with the average trade being worth of $720,841. The most recent stock trade was executed by Robert S Breuil on 14 March 2023, trading 5,000 units of GRAY stock currently worth $27,500.
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Graybug Vision executives and other stock owners filed with the SEC include: